Affiliation:
1. Department of Internal Medicine Kansai Medical University Kori Hospital Neyagawa Osaka Japan
2. Department of Nephrology and Hypertension Dokkyo Medical University Mibu Tochigi Japan
3. Division of Internal Medicine Mooka Hospital Mooka Tochigi Japan
4. Department of Cardiovascular Medicine Ishikiriseiki Hospital Higashiosaka Osaka Japan
Abstract
AbstractThis study assessed the efficacy and safety of sacubitril/valsartan in 23 hemodialysis patients with hypertension (mean age 70 years; male 69.6%) after switching from azilsartan, an angiotensin receptor blocker. Both at baseline and 3 months after the start of sacubitril/valsartan treatment, home blood pressure (BP), BP values during hemodialysis, and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) level were measured. The mean dosage of azilsartan was 30 ± 10 mg/day at baseline and that of sacubitril/valsartan after 3 months of treatment was 204 ± 64 mg/day. After 3 months, significant reductions in mean morning home BP (155 ± 17/80 ± 12 to 147 ± 16/76 ± 11 mmHg), mean nighttime home systolic BP (153 ± 19 to 144 ± 16 mmHg), and median (IQRs) NT‐proBNP level [8124 (2620–13 394) to 6271 (1570–9591) pg/mL] were observed (all P < .05), whereas BP values during hemodialysis did not change significantly. In hemodialysis patients, except for hypotension, sacubitril/valsartan was generally well tolerated, effectively controlled out‐of‐office BP, and improved NT‐proBNP.
Subject
Cardiology and Cardiovascular Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献